Welcome to our dedicated page for Thiogenesis news (Ticker: TTIPF), a resource for investors and traders seeking the latest updates and insights on Thiogenesis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Thiogenesis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Thiogenesis's position in the market.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biotech company, has entered into a consulting and investor relations agreement with Bull Markets Media GmbH, effective February 15, 2025. The German-based digital stock market news portal will analyze opportunities to expand the company's European shareholder base and network.
The agreement includes a C$60,000 consulting fee, with 50% payable upon signing and the remainder due June 1, 2025. Additionally, the consultant will receive 100,000 stock options at $0.64 per share, valid for 3 years, vesting in four equal tranches of 25,000 between May 2025 and February 2026. The 12-month agreement can be renewed annually for up to two additional years.
The TSXV has also given final acceptance of Thiogenesis's IR contract with Triomphe Holdings (Capital Analytica).
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) has announced its common shares are now trading on the OTCQX Best Market under the symbol TTIPF. This represents a significant milestone as OTCQX is the highest-level market of OTC Markets, hosting 12,000 U.S. and global securities.
The company has also secured DTC eligibility status, enabling electronic settlement of shares across the United States and 131 other countries. Thiogenesis will maintain its listing on the TSX Venture Exchange under TTI.
Additionally, the company recently received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for the treatment of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS). The trial's commencement is pending completion of administrative procedures and material provision to trial sites.
Thiogenesis Therapeutics (TSXV: TTI) has received final EMA clearance for its Clinical Trial Application (CTA) Part II to begin a Phase 2 clinical trial of TTI-0102 for MELAS treatment. The trial will be conducted in France and the Netherlands as a randomized, double-blind, placebo-controlled study over 6 months.
The study will involve 12 patients total, with 8 receiving TTI-0102 and 4 receiving placebo. An interim analysis will be conducted after 3 months to assess safety data, pharmacokinetics/pharmacodynamics, and biomarkers. The trial's efficacy endpoints include the 12-Minute Walking Test, Fatigue Severity Scale, and Quality of Life Assessment.
TTI-0102 is designed to increase intracellular antioxidant glutathione and amino acid taurine levels, which are typically deficient in MELAS patients. Currently, there are no approved drugs for MELAS treatment.
Thiogenesis Therapeutics presented updates on two clinical programs in mitochondrial disease at the UMDF Webcast. The company received acceptance of its Clinical Trial Application Part I for MELAS in Europe and submitted Part II in December 2024, planning a Phase 2 trial with 12 patients in Netherlands and France by Q1 2025.
For Leigh Syndrome (LS), following a pre-IND meeting with the FDA in November 2024, the company is filing an IND and plans to initiate a Phase 2a trial in Q1 2025. The company's lead product, TTI-0102, targets oxidative stress in both conditions. MELAS affects approximately 15,000 patients in the US and 20,000 in the EU, while LS occurs in about 1/40,000 births.
Thiogenesis Therapeutics (TSXV: TTI, OTC: TTIPF) has achieved DTC eligibility status in the U.S., enabling electronic settlement of its common shares and supporting its future U.S. listing plans. The company participated in the CEM conference in Miami for investor outreach. Additionally, Thiogenesis issued 521,800 shares at $0.50 per share from exercised Finder's Options, generating $260,900. The company reported $4.15 million in cash and cash equivalents as of September 30, 2024.
Thiogenesis Therapeutics (TSXV: TTI) announces the allowance of a core patent by the European Patent Office titled 'Methods For The Treatment of Cysteamine Sensitive Disorders' (European Patent No. 18858763.8). This patent, set to expire in September 2037, adds to the company's existing patents in the same family granted in the United States (2021) and Japan (2023). The company develops novel thiol compounds, including cysteamine precursors, targeting mitochondrial diseases and related metabolic conditions through their antioxidant and anti-inflammatory properties.
FAQ
What is the current stock price of Thiogenesis (TTIPF)?
What is the market cap of Thiogenesis (TTIPF)?
